Cargando…

Loss of PDPK1 abrogates resistance to gemcitabine in label-retaining pancreatic cancer cells

BACKGROUND: Label-retaining cancer cells (LRCC) have been proposed as a model of slowly cycling cancer stem cells (CSC) which mediate resistance to chemotherapy, tumor recurrence, and metastasis. The molecular mechanisms of chemoresistance in LRCC remain to-date incompletely understood. This study a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Dandan, Mullinax, John E., Aiken, Taylor, Xin, Hongwu, Wiegand, Gordon, Anderson, Andrew, Thorgeirsson, Snorri, Avital, Itzhak, Rudloff, Udo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6069886/ https://www.ncbi.nlm.nih.gov/pubmed/30064387 http://dx.doi.org/10.1186/s12885-018-4690-1

Ejemplares similares

Liver Label Retaining Cancer Cells Are Relatively Resistant to the Reported Anti-Cancer Stem Cell Drug Metformin
por: Xin, Hong-Wu, et al.
Publicado: (2016)

Establishment of Human Ultra-Low Passage Colorectal Cancer Cell Lines Using Spheroids from Fresh Surgical Specimens Suitable for In Vitro and In Vivo Studies
por: Ray, Satyajit, et al.
Publicado: (2012)

Wnt and the Cancer Niche: Paracrine Interactions with Gastrointestinal Cancer Cells Undergoing Asymmetric Cell Division
por: Xin, Hong-Wu, et al.
Publicado: (2013)

Mini-Review: PDPK1 (3-phosphoinositide dependent protein kinase-1), An Emerging Cancer Stem Cell Target
por: Domrachev, Bogdan, et al.
Publicado: (2021)

A Pilot Study Assessing the Potential Role of non-CD133 Colorectal Cancer Stem Cells as Biomarkers
por: Langan, Russell C., et al.
Publicado: (2012)

Downregulating PDPK1 and taking phillyrin as PDPK1-targeting drug protect hepatocytes from alcoholic steatohepatitis by promoting autophagy
por: Zhang, Yuan, et al.
Publicado: (2022)

An integrated transcriptome and epigenome analysis identifies a novel candidate gene for pancreatic cancer
por: Jia, Jinping, et al.
Publicado: (2013)

Targeting S1PR1/STAT3 loop abrogates desmoplasia and chemosensitizes pancreatic cancer to gemcitabine
por: Lankadasari, Manendra Babu, et al.
Publicado: (2018)

Talniflumate abrogates mucin immune suppressive barrier improving efficacy of gemcitabine and nab-paclitaxel treatment in pancreatic cancer
por: Agostini, Antonio, et al.
Publicado: (2023)

SUMOylation of PDPK1 Is required to maintain glycolysis-dependent CD4 T-cell homeostasis
por: Sun, Fei, et al.
Publicado: (2022)

Vascular endothelial PDPK1 plays a pivotal role in the maintenance of pancreatic beta cell mass and function in adult male mice
por: Obata, Atsushi, et al.
Publicado: (2019)

Intralesional injection of rose bengal augments the efficacy of gemcitabine chemotherapy against pancreatic tumors
por: Innamarato, Patrick, et al.
Publicado: (2021)

Possible involvement of the Hedgehog and PDPK1–Akt pathways in the growth and migration of small-cell lung cancer
por: Tang, Naiwang, et al.
Publicado: (2021)

CircRNA ANXA2 Promotes Lung Cancer Proliferation and Metastasis by Upregulating PDPK1 Expression
por: Ju, Yan, et al.
Publicado: (2021)

Colorectal Cancer Biomarkers and the Potential Role of Cancer Stem Cells
por: Langan, Russell C., et al.
Publicado: (2013)

Chlamydia trachomatis Prevents Apoptosis Via Activation of PDPK1-MYC and Enhanced Mitochondrial Binding of Hexokinase II
por: Al-Zeer, Munir A., et al.
Publicado: (2017)

The enhancement of combination of berberine and metformin in inhibition of DNMT1 gene expression through interplay of SP1 and PDPK1
por: Zheng, Fang, et al.
Publicado: (2017)

Interleukin 1β-mediated HOXC10 Overexpression Promotes Hepatocellular Carcinoma Metastasis by Upregulating PDPK1 and VASP
por: Dang, Yunzhi, et al.
Publicado: (2020)

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in treatment of gastric cancer with peritoneal carcinomatosis
por: Ellison, Lynne M., et al.
Publicado: (2017)

Expression of the scaffold connector enhancer of kinase suppressor of Ras 1 (CNKSR1) is correlated with clinical outcome in pancreatic cancer
por: Quadri, Humair S., et al.
Publicado: (2017)

Pancreatic Cancer Chemoresistance to Gemcitabine
por: Amrutkar, Manoj, et al.
Publicado: (2017)

lncRNA‐PDPK2P promotes hepatocellular carcinoma progression through the PDK1/AKT/Caspase 3 pathway
por: Pan, Weidong, et al.
Publicado: (2019)

Merging perspectives: genotype-directed molecular therapy for hereditary diffuse gastric cancer (HDGC) and E-cadherin–EGFR crosstalk
por: Li, Dandan, et al.
Publicado: (2018)

T Cell–Mediated Antitumor Immunity Cooperatively Induced By TGFβR1 Antagonism and Gemcitabine Counteracts Reformation of the Stromal Barrier in Pancreatic Cancer
por: Li, Dandan, et al.
Publicado: (2021)

Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma
por: Klein-Brill, Avital, et al.
Publicado: (2022)

A Randomized, Open-Label, Safety and Exploratory Efficacy Study of Kanglaite Injection (KLTi) plus Gemcitabine versus Gemcitabine in Patients with Advanced Pancreatic Cancer
por: Schwartzberg, Lee S., et al.
Publicado: (2017)

What Makes Cirrhosis Irreversible?—Consideration on Structural Changes
por: Dezső, Katalin, et al.
Publicado: (2022)

Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adaptive multicentre, randomised, open-label, phase 3, superiority trial
por: Bekaii-Saab, Tanios, et al.
Publicado: (2023)

Abrogating cholesterol esterification suppresses growth and metastasis of pancreatic cancer
por: Li, J, et al.
Publicado: (2016)

Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer
por: Dalgleish, Angus G, et al.
Publicado: (2016)

Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer
por: Dalgleish, Angus G, et al.
Publicado: (2016)

Namodenoson Inhibits the Growth of Pancreatic Carcinoma via Deregulation of the Wnt/β-catenin, NF-κB, and RAS Signaling Pathways
por: Itzhak, Inbal, et al.
Publicado: (2023)

Genotoxicity of N-acetylarylamines in the Salmonella/hepatocyte system
por: Thorgeirsson, Snorri S., et al.
Publicado: (1983)

Phosphoinositide‐dependent Kinase‐1 (PDPK1) regulates serum/glucocorticoid‐regulated Kinase 3 (SGK3) for prostate cancer cell survival
por: Nalairndran, Geetha, et al.
Publicado: (2020)

LncRNA CAR10 Upregulates PDPK1 to Promote Cervical Cancer Development by Sponging miR-125b-5p
por: Hu, Tingting, et al.
Publicado: (2020)

Liver Directed Therapy for Renal Cell Carcinoma
por: Langan, Russell C., et al.
Publicado: (2012)

Kinetics of Label Retaining Cells in the Developing Rat Kidneys
por: Wang, Jianwen, et al.
Publicado: (2015)

Novel Strategy with Gemcitabine for Advanced Pancreatic Cancer
por: Komori, Shuji, et al.
Publicado: (2011)

Gemcitabine Therapy in Patients with Advanced Pancreatic Cancer
por: Min, Young Joo, et al.
Publicado: (2002)

Gemcitabine plus S-1 for metastatic pancreatic cancer
por: Zhu, Hong, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_22dgqt1gvmn3n6g9nfntelk24q